Connect with your FASENRA representative and request samples

Input your ZIP code and we’ll contact the FASENRA representative closest to you. Your local representative can also help you obtain samples of FASENRA.

^*Required field

AstraZeneca is committed to helping healthcare professionals provide appropriate care for their patients. Please provide us with this information so that we can keep your records up to date and can send you any information that you request. If in the future you no longer want to receive health-related materials from AstraZeneca, please call 1-800-236-9933. Please visit www.azprivacynotice.com to review our Privacy Notice.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Known hypersensitivity to benralizumab or excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions (eg, anaphylaxis, angioedema, urticaria, rash) have occurred after administration of FASENRA. These reactions generally occur within hours of administration, but in some instances have a delayed onset (ie, days). Discontinue in the event of a hypersensitivity reaction.

Acute Asthma Symptoms or Deteriorating Disease

FASENRA should not be used to treat acute asthma symptoms, acute exacerbations, or acute bronchospasm.

Reduction of Corticosteroid Dosage

Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Parasitic (Helminth) Infection

It is unknown if FASENRA will influence a patient’s response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with FASENRA. If patients become infected while receiving FASENRA and do not respond to anti-helminth treatment, discontinue FASENRA until infection resolves.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥ 5%):

Asthma: headache, pharyngitis
EGPA: headache
HES: headache, hypersensitivity reactions, influenza-like illness

Injection site reactions (eg, pain, erythema, pruritus, papule) occurred at a rate of 2.2% in patients treated with FASENRA compared with 1.9% in patients treated with placebo in asthma exacerbation studies.

USE IN SPECIFIC POPULATIONS

The data on pregnancy exposure from the clinical trials are insufficient to inform on drug-associated risk. Monoclonal antibodies such as benralizumab are transported across the placenta during the third trimester of pregnancy; therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy.

INDICATIONS

FASENRA is indicated for:

the add-on maintenance treatment of patients with severe asthma aged 6 years and older and with an eosinophilic phenotype. FASENRA is not indicated for the relief of acute bronchospasm or status asthmaticus
the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA)
the treatment of adult and adolescent patients aged 12 years and older with hypereosinophilic syndrome (HES) without an identifiable non-hematologic secondary cause

Please read full Prescribing Information, including Patient Information.

You may report side effects related to AstraZeneca products .

References

Reference

1. FASENRA® (benralizumab) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2026.

1. FASENRA® (benralizumab) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2026.
2. Ogbogu PU, Roufosse F, Akuthota P, et al. Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. Nat Med. Published online March 31, 2026. doi:10.1038/s41591-026-04315-8 3. Ogbogu PU, Roufosse F, Akuthota P, et al. Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. Nat Med. Supplementary information published online March 31, 2026. doi:10.1038/s41591-026-04315-8

1. Khoury P, Akuthota P, Kwon N, Steinfeld J, Roufosse F. HES and EGPA: two sides of the same coin. Mayo Clin Proc. 2023;98(7):1054-1070. 2. Valent P, Klion AD, Roufosse F, et al. Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes. Allergy. 2023;78(1):47-59. 3. Silver J, Kovalszki A, Strobel MJ, et al. Burden of hypereosinophilic syndromes in the United States: patients' perspective. J Allergy Clin Immunol Glob. 2025;4(3):100501. 4. Dolin P, Pongdee T, Jain P, et al. Disease burden of idiopathic and lymphocytic hypereosinophilic syndrome in the United States: evidence from a real-world retrospective study of de-identified electronic health records and insurance claims. Poster presented at: The American Society of Hematology Annual Meeting; December 7–10, 2024; San Diego, CA. Poster 2316.

1. FASENRA® (benralizumab) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2026.

1. Ogbogu PU, Roufosse F, Akuthota P, et al. Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. Nat Med. Published online March 31, 2026. doi:10.1038/s41591-026-04315-8 2. FASENRA® (benralizumab) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2026. 3. Data on File, US-107579, AZPLP.

1. FASENRA® (benralizumab) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2026.
2. Nucala® (mepolizumab) [package insert]. Philadelphia, PA: GlaxoSmithKline LLC; August 2025.